Survival and safety of exemestane versus tamoxifen
after 2-3 years' tamoxifen treatment (intergroup exemestane study): a
randomised controlled trial
Coombes RC et al
. LANCET. 2007.
A double-blind randomized trial to test whether, after two to three
years of tamoxifen therapy, switching to exemestane was more effective
than continuing tamoxifen therapy for the remainder of the 5 years of
treatment.
A randomized trial of exemestane after two to three
years of tamoxifen therapy in postmenopausal women with primary breast
cancer
Coombes RC et al.
N Engl J Med. 2004.
An international, intergroup, phase III, randomized, double-blind
trial comparing the efficacy and safety of continued adjuvant tamoxifen
therapy with that of exemestane therapy in postmenopausal women with
primary breast cancer who remain free of disease after receiving
adjuvant tamoxifen therapy for two to three years.
Exemestane is superior to megestrol acetate after
tamoxifen failure in postmenopausal women with advanced breast cancer:
results of a phase III randomized double-blind trial.
Kaufmann M et al.
J Clin Oncol. 2006.
This phase III, double-blind, randomized multicenter study evaluated
the efficacy, pharmacodynamics, and safety of the oral aromatase
inactivator exemestane versus megestrol acetate in postmenopausal women
with progressive advanced breast cancer who experienced failure of
tamoxifen.
Progress and promise: highlights of the
international expert censensus on the primary therapy of early breast
cancer 2007
Goldhirsch A et al.
Ann Oncol. 2007.
Summary of the 10th St Gallen expert censensus meeting, which
redefined and extended a target-oriented approach to adjuvant systemic
therapy of early breast cancer.
Effects of exemestane administered for 2 years
versus placebo on bone mineral density, bone biomarkers, and plasma
lipids in patients with surgically resected early breast
cancer
Lonning PE et al.
N Engl J Med. 2004.
A double-blind study researching the effect of exemestane on bone mass
density on postmenopausal women with low-risk, surgically treated early
breast cancer or ductal carcinoma in situ.
American Society of Clinical Oncology Technology
Assessment on the use of aromatase inhibitors as adjuvant therapy for
postmenopausal women with hormone receptor-positive breast cancer:
status report 2004 Winer et al.
J Clin Oncol.
2005.
An update to the ASCO technology assessment on adjuvant use of
aromatase inhibitors, using the results of four phase III randomized
adjuvant trials.
View more reprints and other AROMASIN-related material in the
Clinical Library.
When you click on an item, it will open in a new window.
In order to view these PDF documents, you must have
Adobe Reader installed on your computer. If you do not have Adobe
Reader, download it from the Adobe Web site.
Note that the Adobe Web site is neither owned nor controlled by
Pfizer. Pfizer is not responsible for the content or services on that
site.
Adobe, the Adobe logo, and Reader are registered trademarks of Adobe
Systems Incorporated in the United States and/or other countries.